P.019 Safe prescribing of antipsychotic drugs in the elderly - Parkinson Disease
Background: The Canadian Guideline for Parkinson Disease (PD) indicates clozapine and quetiapine are considered the only safe antipsychotics for people with PD, to avoid potentially exacerbating motor symptoms. In response to safety events in our centre, we explore contraindicated antipsychotic pres...
Gespeichert in:
Veröffentlicht in: | Canadian journal of neurological sciences 2023-06, Vol.50 (s2), p.S62-S62 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S62 |
---|---|
container_issue | s2 |
container_start_page | S62 |
container_title | Canadian journal of neurological sciences |
container_volume | 50 |
creator | Wile, D Penner, LJ |
description | Background: The Canadian Guideline for Parkinson Disease (PD) indicates clozapine and quetiapine are considered the only safe antipsychotics for people with PD, to avoid potentially exacerbating motor symptoms. In response to safety events in our centre, we explore contraindicated antipsychotic prescriptions being administered to hospital inpatients with PD to determine common factors and develop approaches to prevent future occurrences. Methods: Following a privacy impact analysis, the Interior Health Quality Improvement & Patient Safety Office identified inpatients at Kelowna General Hospital, between December 2018 and June 2021, with a coded diagnosis of PD. Pharmacy medication order and dispensing data were cross-referenced to determine patients exposed to a contraindicated antipsychotic for further chart analysis. Results: Of the 140 admissions with a PD diagnosis, 17 had at least one contraindicated antipsychotic prescribed or dispensed (12.1%). Loxapine (7) and haloperidol (6) were the most frequently prescribed. This occurred despite a diagnosis of PD being noted on admission in 14 cases, and 13 cases were known to be taking levodopa. Conclusions: These results demonstrate additional safety measures are needed to reduce the frequency of contraindicated antipsychotic prescriptions in this population. We propose developing a stepwise plan for behaviour de-escalation and pharmacological management. |
doi_str_mv | 10.1017/cjn.2023.123 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2887050987</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_cjn_2023_123</cupid><sourcerecordid>2887050987</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1423-4f1b6f6407f4c627c960eef5e8ae6e068dab89c126449f137c243ada8efdbd8d3</originalsourceid><addsrcrecordid>eNptkEtLAzEYRYMoWB87f0DArTMmmUySWUp9QsGCug6Z5Eub2mbGZLrov3dKC25c3c2598JB6IaSkhIq7-0qloywqqSsOkETRmpZEFrXp2hCKioLKiQ9Rxc5rwhhohZ8gubzktAGfxgPuE-QbQptiAvceWziEPq8s8tuCBa7tF1kHCIeloBh7SCtd7jAc5O-Q8xdxI8hg8lwhc68WWe4PuYl-np--py-FrP3l7fpw6ywlLOq4J62wgtOpOdWMGkbQQB8DcqAACKUM61qLGWC88bTSlrGK-OMAu9ap1x1iW4Pu33qfraQB73qtimOl5opJUlNGiVH6u5A2dTlnMDrPoWNSTtNid4706MzvXemR2cjXh5xs2lTcAv4W_238AvfcW16</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2887050987</pqid></control><display><type>article</type><title>P.019 Safe prescribing of antipsychotic drugs in the elderly - Parkinson Disease</title><source>Cambridge University Press Journals Complete</source><creator>Wile, D ; Penner, LJ</creator><creatorcontrib>Wile, D ; Penner, LJ</creatorcontrib><description>Background: The Canadian Guideline for Parkinson Disease (PD) indicates clozapine and quetiapine are considered the only safe antipsychotics for people with PD, to avoid potentially exacerbating motor symptoms. In response to safety events in our centre, we explore contraindicated antipsychotic prescriptions being administered to hospital inpatients with PD to determine common factors and develop approaches to prevent future occurrences. Methods: Following a privacy impact analysis, the Interior Health Quality Improvement & Patient Safety Office identified inpatients at Kelowna General Hospital, between December 2018 and June 2021, with a coded diagnosis of PD. Pharmacy medication order and dispensing data were cross-referenced to determine patients exposed to a contraindicated antipsychotic for further chart analysis. Results: Of the 140 admissions with a PD diagnosis, 17 had at least one contraindicated antipsychotic prescribed or dispensed (12.1%). Loxapine (7) and haloperidol (6) were the most frequently prescribed. This occurred despite a diagnosis of PD being noted on admission in 14 cases, and 13 cases were known to be taking levodopa. Conclusions: These results demonstrate additional safety measures are needed to reduce the frequency of contraindicated antipsychotic prescriptions in this population. We propose developing a stepwise plan for behaviour de-escalation and pharmacological management.</description><identifier>ISSN: 0317-1671</identifier><identifier>EISSN: 2057-0155</identifier><identifier>DOI: 10.1017/cjn.2023.123</identifier><language>eng</language><publisher>New York, USA: Cambridge University Press</publisher><subject>Abstracts ; Adult Neurology (CNS/CSC) ; Antipsychotics ; Contraindications ; Movement Disorders ; Older people ; Parkinson's disease ; Patient safety ; Poster Presentations ; Psychotropic drugs</subject><ispartof>Canadian journal of neurological sciences, 2023-06, Vol.50 (s2), p.S62-S62</ispartof><rights>The Author(s), 2023. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S0317167123001233/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>164,314,780,784,27924,27925,55628</link.rule.ids></links><search><creatorcontrib>Wile, D</creatorcontrib><creatorcontrib>Penner, LJ</creatorcontrib><title>P.019 Safe prescribing of antipsychotic drugs in the elderly - Parkinson Disease</title><title>Canadian journal of neurological sciences</title><addtitle>Can. J. Neurol. Sci</addtitle><description>Background: The Canadian Guideline for Parkinson Disease (PD) indicates clozapine and quetiapine are considered the only safe antipsychotics for people with PD, to avoid potentially exacerbating motor symptoms. In response to safety events in our centre, we explore contraindicated antipsychotic prescriptions being administered to hospital inpatients with PD to determine common factors and develop approaches to prevent future occurrences. Methods: Following a privacy impact analysis, the Interior Health Quality Improvement & Patient Safety Office identified inpatients at Kelowna General Hospital, between December 2018 and June 2021, with a coded diagnosis of PD. Pharmacy medication order and dispensing data were cross-referenced to determine patients exposed to a contraindicated antipsychotic for further chart analysis. Results: Of the 140 admissions with a PD diagnosis, 17 had at least one contraindicated antipsychotic prescribed or dispensed (12.1%). Loxapine (7) and haloperidol (6) were the most frequently prescribed. This occurred despite a diagnosis of PD being noted on admission in 14 cases, and 13 cases were known to be taking levodopa. Conclusions: These results demonstrate additional safety measures are needed to reduce the frequency of contraindicated antipsychotic prescriptions in this population. We propose developing a stepwise plan for behaviour de-escalation and pharmacological management.</description><subject>Abstracts</subject><subject>Adult Neurology (CNS/CSC)</subject><subject>Antipsychotics</subject><subject>Contraindications</subject><subject>Movement Disorders</subject><subject>Older people</subject><subject>Parkinson's disease</subject><subject>Patient safety</subject><subject>Poster Presentations</subject><subject>Psychotropic drugs</subject><issn>0317-1671</issn><issn>2057-0155</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkEtLAzEYRYMoWB87f0DArTMmmUySWUp9QsGCug6Z5Eub2mbGZLrov3dKC25c3c2598JB6IaSkhIq7-0qloywqqSsOkETRmpZEFrXp2hCKioLKiQ9Rxc5rwhhohZ8gubzktAGfxgPuE-QbQptiAvceWziEPq8s8tuCBa7tF1kHCIeloBh7SCtd7jAc5O-Q8xdxI8hg8lwhc68WWe4PuYl-np--py-FrP3l7fpw6ywlLOq4J62wgtOpOdWMGkbQQB8DcqAACKUM61qLGWC88bTSlrGK-OMAu9ap1x1iW4Pu33qfraQB73qtimOl5opJUlNGiVH6u5A2dTlnMDrPoWNSTtNid4706MzvXemR2cjXh5xs2lTcAv4W_238AvfcW16</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Wile, D</creator><creator>Penner, LJ</creator><general>Cambridge University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>202306</creationdate><title>P.019 Safe prescribing of antipsychotic drugs in the elderly - Parkinson Disease</title><author>Wile, D ; Penner, LJ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1423-4f1b6f6407f4c627c960eef5e8ae6e068dab89c126449f137c243ada8efdbd8d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abstracts</topic><topic>Adult Neurology (CNS/CSC)</topic><topic>Antipsychotics</topic><topic>Contraindications</topic><topic>Movement Disorders</topic><topic>Older people</topic><topic>Parkinson's disease</topic><topic>Patient safety</topic><topic>Poster Presentations</topic><topic>Psychotropic drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wile, D</creatorcontrib><creatorcontrib>Penner, LJ</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Canadian journal of neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wile, D</au><au>Penner, LJ</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P.019 Safe prescribing of antipsychotic drugs in the elderly - Parkinson Disease</atitle><jtitle>Canadian journal of neurological sciences</jtitle><addtitle>Can. J. Neurol. Sci</addtitle><date>2023-06</date><risdate>2023</risdate><volume>50</volume><issue>s2</issue><spage>S62</spage><epage>S62</epage><pages>S62-S62</pages><issn>0317-1671</issn><eissn>2057-0155</eissn><abstract>Background: The Canadian Guideline for Parkinson Disease (PD) indicates clozapine and quetiapine are considered the only safe antipsychotics for people with PD, to avoid potentially exacerbating motor symptoms. In response to safety events in our centre, we explore contraindicated antipsychotic prescriptions being administered to hospital inpatients with PD to determine common factors and develop approaches to prevent future occurrences. Methods: Following a privacy impact analysis, the Interior Health Quality Improvement & Patient Safety Office identified inpatients at Kelowna General Hospital, between December 2018 and June 2021, with a coded diagnosis of PD. Pharmacy medication order and dispensing data were cross-referenced to determine patients exposed to a contraindicated antipsychotic for further chart analysis. Results: Of the 140 admissions with a PD diagnosis, 17 had at least one contraindicated antipsychotic prescribed or dispensed (12.1%). Loxapine (7) and haloperidol (6) were the most frequently prescribed. This occurred despite a diagnosis of PD being noted on admission in 14 cases, and 13 cases were known to be taking levodopa. Conclusions: These results demonstrate additional safety measures are needed to reduce the frequency of contraindicated antipsychotic prescriptions in this population. We propose developing a stepwise plan for behaviour de-escalation and pharmacological management.</abstract><cop>New York, USA</cop><pub>Cambridge University Press</pub><doi>10.1017/cjn.2023.123</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0317-1671 |
ispartof | Canadian journal of neurological sciences, 2023-06, Vol.50 (s2), p.S62-S62 |
issn | 0317-1671 2057-0155 |
language | eng |
recordid | cdi_proquest_journals_2887050987 |
source | Cambridge University Press Journals Complete |
subjects | Abstracts Adult Neurology (CNS/CSC) Antipsychotics Contraindications Movement Disorders Older people Parkinson's disease Patient safety Poster Presentations Psychotropic drugs |
title | P.019 Safe prescribing of antipsychotic drugs in the elderly - Parkinson Disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T03%3A58%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P.019%20Safe%20prescribing%20of%20antipsychotic%20drugs%20in%20the%20elderly%20-%20Parkinson%20Disease&rft.jtitle=Canadian%20journal%20of%20neurological%20sciences&rft.au=Wile,%20D&rft.date=2023-06&rft.volume=50&rft.issue=s2&rft.spage=S62&rft.epage=S62&rft.pages=S62-S62&rft.issn=0317-1671&rft.eissn=2057-0155&rft_id=info:doi/10.1017/cjn.2023.123&rft_dat=%3Cproquest_cross%3E2887050987%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2887050987&rft_id=info:pmid/&rft_cupid=10_1017_cjn_2023_123&rfr_iscdi=true |